AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

BridgeBio Pharma director Charles J. Homcy received new equity compensation grants on June 20, 2025, consisting of:

  • 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, vesting over 3 years through June 20, 2028
  • 8,425 Stock Options with an exercise price of $41.73, vesting over 3 years through June 20, 2028

Following these transactions, Homcy directly owns 1,236,674 shares of common stock. Both the RSUs and stock options are subject to continued service on BridgeBio's board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan. This Form 4 filing represents standard board member equity compensation.

Il direttore di BridgeBio Pharma, Charles J. Homcy, ha ricevuto nuove assegnazioni di compensi azionari in data 20 giugno 2025, che comprendono:

  • 6.589 Unit脿 Azionarie Vincolate (RSU) con prezzo di esercizio pari a 0$, con maturazione in 3 anni fino al 20 giugno 2028
  • 8.425 Opzioni Azionarie con prezzo di esercizio di 41,73$, con maturazione in 3 anni fino al 20 giugno 2028

Dopo queste operazioni, Homcy detiene direttamente 1.236.674 azioni di azioni ordinarie. Sia le RSU che le opzioni azionarie sono soggette alla permanenza nel consiglio di amministrazione di BridgeBio. Le assegnazioni sono state effettuate in base al Piano di Opzioni Azionarie e Incentivi modificato e riformulato del 2021 della societ脿. Questa comunicazione Form 4 rappresenta la normale compensazione azionaria per i membri del consiglio.

El director de BridgeBio Pharma, Charles J. Homcy, recibi贸 nuevas concesiones de compensaci贸n en acciones el 20 de junio de 2025, que consisten en:

  • 6.589 Unidades de Acciones Restringidas (RSU) con un precio de ejercicio de $0, que se consolidan durante 3 a帽os hasta el 20 de junio de 2028
  • 8.425 Opciones sobre Acciones con un precio de ejercicio de $41.73, que se consolidan durante 3 a帽os hasta el 20 de junio de 2028

Tras estas transacciones, Homcy posee directamente 1.236.674 acciones ordinarias. Tanto las RSU como las opciones est谩n sujetas a la condici贸n de continuar en el consejo de administraci贸n de BridgeBio. Las concesiones se realizaron bajo el Plan de Opciones sobre Acciones e Incentivos Modificado y Reformulado de 2021 de la compa帽铆a. Esta presentaci贸n del Formulario 4 representa la compensaci贸n est谩ndar en acciones para miembros del consejo.

BridgeBio Pharma 鞚挫偓 Charles J. Homcy电� 2025雲� 6鞗� 20鞚�鞐� 雼れ潓瓿� 臧欖潃 靸堧鞖� 欤检嫕 氤挫儊 攵�鞐ゼ 氚涭晿鞀惦媹雼�:

  • 6,589 鞝滍暅 欤检嫕 雼渼(RSU)搿� 頄夓偓臧�瓴╈潃 $0鞚措┌, 3雲勳棎 瓯胳硱 2028雲� 6鞗� 20鞚缄箤歆� 甓岆Μ臧� 旆摑霅╇媹雼�.
  • 8,425 欤检嫕 鞓奠厴鞙茧 頄夓偓臧�瓴╈潃 $41.73鞚措┌, 3雲勳棎 瓯胳硱 2028雲� 6鞗� 20鞚缄箤歆� 甓岆Μ臧� 旆摑霅╇媹雼�.

鞚� 瓯半灅 頉� Homcy电� 歆侅爲 氤错喌欤� 1,236,674欤�毳� 氤挫湢頃橁矊 霅╇媹雼�. RSU鞕� 欤检嫕 鞓奠厴 氇憪 BridgeBio 鞚挫偓須岇棎靹� 瓿勳啀 攴茧頃挫暭 頃樀鐢 臁瓣贝鞚� 攵欖柎 鞛堨姷雼堧嫟. 鞚� 攵�鞐鐢 須岇偓鞚� 2021雲� 臧滌爼 氚� 鞛爼牍勲悳 欤检嫕 鞓奠厴 氚� 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�. 鞚� Form 4 鞝滌稖鞚� 鞚挫偓須� 甑劚鞗愳棎 雽�頃� 響滌 欤检嫕 氤挫儊鞚� 雮橅儉雰呺媹雼�.

Le directeur de BridgeBio Pharma, Charles J. Homcy, a re莽u de nouvelles attributions de r茅mun茅ration en actions le 20 juin 2025, comprenant :

  • 6 589 unit茅s d鈥檃ctions restreintes (RSU) avec un prix d鈥檈xercice de 0 $, acquises sur 3 ans jusqu鈥檃u 20 juin 2028
  • 8 425 options d鈥檃chat d鈥檃ctions avec un prix d鈥檈xercice de 41,73 $, acquises sur 3 ans jusqu鈥檃u 20 juin 2028

脌 la suite de ces op茅rations, Homcy d茅tient directement 1 236 674 actions ordinaires. Les RSU et les options d鈥檃chat sont soumises 脿 la condition de continuer 脿 si茅ger au conseil d鈥檃dministration de BridgeBio. Les attributions ont 茅t茅 effectu茅es dans le cadre du Plan d鈥檕ptions d鈥檃chat d鈥檃ctions et d鈥檌ncitations modifi茅 et r茅vis茅 de 2021 de la soci茅t茅. Ce d茅p么t du formulaire 4 repr茅sente une r茅mun茅ration en actions standard pour les membres du conseil.

Der Direktor von BridgeBio Pharma, Charles J. Homcy, erhielt am 20. Juni 2025 neue Aktienverg眉tungszuteilungen, bestehend aus:

  • 6.589 Restricted Stock Units (RSUs) mit einem Aus眉bungspreis von 0 $, die 眉ber 3 Jahre bis zum 20. Juni 2028 vesten
  • 8.425 Aktienoptionen mit einem Aus眉bungspreis von 41,73 $, die 眉ber 3 Jahre bis zum 20. Juni 2028 vesten

Nach diesen Transaktionen besitzt Homcy direkt 1.236.674 Stammaktien. Sowohl die RSUs als auch die Aktienoptionen sind an eine fortlaufende T盲tigkeit im Vorstand von BridgeBio gebunden. Die Zuteilungen erfolgten im Rahmen des ge盲nderten und neu gefassten Aktienoptions- und Anreizplans von 2021 des Unternehmens. Diese Form-4-Meldung stellt die 眉bliche Aktienverg眉tung f眉r Vorstandsmitglieder dar.

Positive
  • None.
Negative
  • None.

Il direttore di BridgeBio Pharma, Charles J. Homcy, ha ricevuto nuove assegnazioni di compensi azionari in data 20 giugno 2025, che comprendono:

  • 6.589 Unit脿 Azionarie Vincolate (RSU) con prezzo di esercizio pari a 0$, con maturazione in 3 anni fino al 20 giugno 2028
  • 8.425 Opzioni Azionarie con prezzo di esercizio di 41,73$, con maturazione in 3 anni fino al 20 giugno 2028

Dopo queste operazioni, Homcy detiene direttamente 1.236.674 azioni di azioni ordinarie. Sia le RSU che le opzioni azionarie sono soggette alla permanenza nel consiglio di amministrazione di BridgeBio. Le assegnazioni sono state effettuate in base al Piano di Opzioni Azionarie e Incentivi modificato e riformulato del 2021 della societ脿. Questa comunicazione Form 4 rappresenta la normale compensazione azionaria per i membri del consiglio.

El director de BridgeBio Pharma, Charles J. Homcy, recibi贸 nuevas concesiones de compensaci贸n en acciones el 20 de junio de 2025, que consisten en:

  • 6.589 Unidades de Acciones Restringidas (RSU) con un precio de ejercicio de $0, que se consolidan durante 3 a帽os hasta el 20 de junio de 2028
  • 8.425 Opciones sobre Acciones con un precio de ejercicio de $41.73, que se consolidan durante 3 a帽os hasta el 20 de junio de 2028

Tras estas transacciones, Homcy posee directamente 1.236.674 acciones ordinarias. Tanto las RSU como las opciones est谩n sujetas a la condici贸n de continuar en el consejo de administraci贸n de BridgeBio. Las concesiones se realizaron bajo el Plan de Opciones sobre Acciones e Incentivos Modificado y Reformulado de 2021 de la compa帽铆a. Esta presentaci贸n del Formulario 4 representa la compensaci贸n est谩ndar en acciones para miembros del consejo.

BridgeBio Pharma 鞚挫偓 Charles J. Homcy电� 2025雲� 6鞗� 20鞚�鞐� 雼れ潓瓿� 臧欖潃 靸堧鞖� 欤检嫕 氤挫儊 攵�鞐ゼ 氚涭晿鞀惦媹雼�:

  • 6,589 鞝滍暅 欤检嫕 雼渼(RSU)搿� 頄夓偓臧�瓴╈潃 $0鞚措┌, 3雲勳棎 瓯胳硱 2028雲� 6鞗� 20鞚缄箤歆� 甓岆Μ臧� 旆摑霅╇媹雼�.
  • 8,425 欤检嫕 鞓奠厴鞙茧 頄夓偓臧�瓴╈潃 $41.73鞚措┌, 3雲勳棎 瓯胳硱 2028雲� 6鞗� 20鞚缄箤歆� 甓岆Μ臧� 旆摑霅╇媹雼�.

鞚� 瓯半灅 頉� Homcy电� 歆侅爲 氤错喌欤� 1,236,674欤�毳� 氤挫湢頃橁矊 霅╇媹雼�. RSU鞕� 欤检嫕 鞓奠厴 氇憪 BridgeBio 鞚挫偓須岇棎靹� 瓿勳啀 攴茧頃挫暭 頃樀鐢 臁瓣贝鞚� 攵欖柎 鞛堨姷雼堧嫟. 鞚� 攵�鞐鐢 須岇偓鞚� 2021雲� 臧滌爼 氚� 鞛爼牍勲悳 欤检嫕 鞓奠厴 氚� 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�. 鞚� Form 4 鞝滌稖鞚� 鞚挫偓須� 甑劚鞗愳棎 雽�頃� 響滌 欤检嫕 氤挫儊鞚� 雮橅儉雰呺媹雼�.

Le directeur de BridgeBio Pharma, Charles J. Homcy, a re莽u de nouvelles attributions de r茅mun茅ration en actions le 20 juin 2025, comprenant :

  • 6 589 unit茅s d鈥檃ctions restreintes (RSU) avec un prix d鈥檈xercice de 0 $, acquises sur 3 ans jusqu鈥檃u 20 juin 2028
  • 8 425 options d鈥檃chat d鈥檃ctions avec un prix d鈥檈xercice de 41,73 $, acquises sur 3 ans jusqu鈥檃u 20 juin 2028

脌 la suite de ces op茅rations, Homcy d茅tient directement 1 236 674 actions ordinaires. Les RSU et les options d鈥檃chat sont soumises 脿 la condition de continuer 脿 si茅ger au conseil d鈥檃dministration de BridgeBio. Les attributions ont 茅t茅 effectu茅es dans le cadre du Plan d鈥檕ptions d鈥檃chat d鈥檃ctions et d鈥檌ncitations modifi茅 et r茅vis茅 de 2021 de la soci茅t茅. Ce d茅p么t du formulaire 4 repr茅sente une r茅mun茅ration en actions standard pour les membres du conseil.

Der Direktor von BridgeBio Pharma, Charles J. Homcy, erhielt am 20. Juni 2025 neue Aktienverg眉tungszuteilungen, bestehend aus:

  • 6.589 Restricted Stock Units (RSUs) mit einem Aus眉bungspreis von 0 $, die 眉ber 3 Jahre bis zum 20. Juni 2028 vesten
  • 8.425 Aktienoptionen mit einem Aus眉bungspreis von 41,73 $, die 眉ber 3 Jahre bis zum 20. Juni 2028 vesten

Nach diesen Transaktionen besitzt Homcy direkt 1.236.674 Stammaktien. Sowohl die RSUs als auch die Aktienoptionen sind an eine fortlaufende T盲tigkeit im Vorstand von BridgeBio gebunden. Die Zuteilungen erfolgten im Rahmen des ge盲nderten und neu gefassten Aktienoptions- und Anreizplans von 2021 des Unternehmens. Diese Form-4-Meldung stellt die 眉bliche Aktienverg眉tung f眉r Vorstandsmitglieder dar.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HOMCY CHARLES J
(Last) (First) (Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A(1) 6,589 A $0(2) 1,236,674 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $41.73 06/20/2025 A 8,425 (3) 06/19/2035 Common Stock 8,425 $0 8,425 D
Explanation of Responses:
1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
/s/ Charles J. Homcy, M.D. 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many BBIO shares did Charles Homcy receive in restricted stock units (RSUs) on June 20, 2025?

Charles Homcy received 6,589 restricted stock units (RSUs) of BBIO on June 20, 2025. These RSUs will vest over three years, with one-third vesting each year starting from June 20, 2025, until fully vested on June 20, 2028.

What stock options were granted to BBIO director Charles Homcy in June 2025?

Charles Homcy was granted stock options to purchase 8,425 shares of BBIO common stock at an exercise price of $41.73 per share on June 20, 2025. The options expire on June 19, 2035, and vest over three years with one-third vesting each year.

How many shares of BBIO does Charles Homcy own directly after the June 2025 transactions?

Following the reported transactions, Charles Homcy directly owns 1,236,674 shares of BBIO common stock, as indicated in Table I of the Form 4 filing under the 'Amount of Securities Beneficially Owned Following Reported Transaction(s)' column.

What is the vesting schedule for BBIO director Charles Homcy's June 2025 equity grants?

Both the RSUs and stock options granted to Charles Homcy on June 20, 2025, follow the same vesting schedule: one-third will vest each year over three years, starting from June 20, 2025, with full vesting on June 20, 2028. The vesting is subject to Homcy's continued service on BBIO's board of directors.
Stock BBIO logo
Bridgebio Pharma

NASDAQ:BBIO

BBIO Rankings

#930 Ranked by Market Cap
N/A Ranked by Dividends

BBIO Latest News

Aug 5, 2025
BridgeBio Reports Second Quarter 2025聽Financial Results and Business Updates
Jul 23, 2025
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
Jul 22, 2025
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
Jun 30, 2025
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA庐 European Royalty
Jun 26, 2025
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

BBIO Latest SEC Filings

Aug 12, 2025
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity
Aug 11, 2025
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity
Aug 11, 2025
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity
Aug 11, 2025
[144] BridgeBio Pharma, Inc. SEC Filing
Aug 8, 2025
[144] BridgeBio Pharma, Inc. SEC Filing

BBIO Stock Data

9.22B
164.71M
4.96%
97.09%
10.26%
Biotechnology
Pharmaceutical Preparations
United States
PALO ALTO